MX2017004473A - Formulaciones de betalactamasa y usos de las mismas. - Google Patents
Formulaciones de betalactamasa y usos de las mismas.Info
- Publication number
- MX2017004473A MX2017004473A MX2017004473A MX2017004473A MX2017004473A MX 2017004473 A MX2017004473 A MX 2017004473A MX 2017004473 A MX2017004473 A MX 2017004473A MX 2017004473 A MX2017004473 A MX 2017004473A MX 2017004473 A MX2017004473 A MX 2017004473A
- Authority
- MX
- Mexico
- Prior art keywords
- beta
- lactamase
- formulations
- lactamase formulations
- release
- Prior art date
Links
- 108090000204 Dipeptidase 1 Proteins 0.000 title abstract 5
- 102000006635 beta-lactamase Human genes 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 210000000936 intestine Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2873—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
- C12Y305/02006—Beta-lactamase (3.5.2.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462061507P | 2014-10-08 | 2014-10-08 | |
| US201562126556P | 2015-02-28 | 2015-02-28 | |
| US201562205443P | 2015-08-14 | 2015-08-14 | |
| PCT/US2015/054606 WO2016057744A1 (en) | 2014-10-08 | 2015-10-08 | Beta-lactamase formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017004473A true MX2017004473A (es) | 2017-10-12 |
Family
ID=55653744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004473A MX2017004473A (es) | 2014-10-08 | 2015-10-08 | Formulaciones de betalactamasa y usos de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10105322B2 (enExample) |
| EP (1) | EP3204495B1 (enExample) |
| JP (1) | JP6672277B2 (enExample) |
| KR (1) | KR102467968B1 (enExample) |
| CN (1) | CN107148473B (enExample) |
| AU (1) | AU2015330937B2 (enExample) |
| CA (1) | CA2962959C (enExample) |
| ES (1) | ES2806426T3 (enExample) |
| MX (1) | MX2017004473A (enExample) |
| WO (1) | WO2016057744A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2958755C (en) | 2014-08-28 | 2023-02-28 | Synthetic Biologics, Inc. | E. coli-based production of beta-lactamase |
| EP3236993B1 (en) | 2014-12-23 | 2023-09-13 | Theriva Biologics, Inc. | Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics |
| WO2016137993A1 (en) | 2015-02-23 | 2016-09-01 | Synthetic Biologics, Inc. | Carbapenemases for use with antibiotics for the protection of the intestinal microbiome |
| EP3265119B1 (en) | 2015-03-06 | 2023-10-11 | Theriva Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
| WO2018005606A1 (en) * | 2016-06-28 | 2018-01-04 | Synthetic Biologics, Inc. | Microbiome protection from oral antibiotics |
| SG10201609137PA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Gamma-polyglutamic acid and zinc compositions |
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| US20190275120A1 (en) * | 2016-11-01 | 2019-09-12 | Synthetic Biologics, Inc. | Methods and compositions for attenuating antibiotic resistance |
| WO2018175414A1 (en) * | 2017-03-21 | 2018-09-27 | Synthetic Biologics, Inc. | Beta-lactamase formulations |
| EP3701022B1 (en) * | 2017-10-25 | 2023-03-01 | Da Volterra | Beta-lactamase variants |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| KR20210040395A (ko) * | 2018-08-05 | 2021-04-13 | 다 볼떼라 | 이식편 대 숙주 질환의 치료를 위한 조성물 |
| JP2022532162A (ja) * | 2019-05-06 | 2022-07-13 | シンセティック・バイオロジクス・インコーポレイテッド | 移植片対宿主病の処置のためのβ－ラクタマーゼ組成物 |
| CA3170780A1 (en) * | 2020-03-10 | 2021-09-16 | Sean Thomas Curtin | System and methods for mammalian transfer learning |
| CN112137984B (zh) * | 2020-10-30 | 2023-02-03 | 四川制药制剂有限公司 | 头孢克洛胶囊及其制备工艺 |
| WO2023168316A1 (en) * | 2022-03-04 | 2023-09-07 | Michael Ogburn | Enteric coated dry powdered cannabinoid formulations |
| CN116790567A (zh) * | 2022-12-30 | 2023-09-22 | 扬州大学 | 来源于土壤宏基因组的β-内酰胺酶及其应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL197650A (enExample) | 1954-05-29 | |||
| US2941995A (en) | 1957-08-02 | 1960-06-21 | Beecham Res Lab | Recovery of solid 6-aminopenicillanic acid |
| US2982696A (en) | 1959-05-01 | 1961-05-02 | Schenley Ind Inc | Ion-exchange procedures for the purification of penicillinase |
| US3070511A (en) | 1960-02-10 | 1962-12-25 | Lepetit Spa | Process for preparing 6-aminopenicillanic acid |
| US3150059A (en) | 1962-12-26 | 1964-09-22 | Lilly Co Eli | Penicillin deacylation via actinoplanaceae fermentation |
| US3239394A (en) | 1964-06-15 | 1966-03-08 | Merck & Co Inc | Process for producing 7-amino-cephalosporanic acid |
| US3499909A (en) | 1966-05-18 | 1970-03-10 | Koninklijke Gist Spiritus | Process for production of 6-aminopenicillanic acid |
| US3488729A (en) | 1966-08-22 | 1970-01-06 | Lilly Co Eli | Cephalothin ester |
| GB1241844A (en) | 1968-08-23 | 1971-08-04 | Beecham Group Ltd | Penicillins |
| GB1463513A (en) | 1974-08-13 | 1977-02-02 | Beecham Group Ltd | Enzymes |
| FI59265C (fi) | 1974-08-13 | 1981-07-10 | Beecham Group Ltd | Foerfarande foer framstaellning av 6-aminopenicillansyra |
| US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| GB2199582A (en) | 1987-01-07 | 1988-07-13 | Bayer Ag | Analogues of pancreatic secretory trypsin inhibitor |
| FR2613624B1 (fr) | 1987-04-10 | 1990-11-23 | Roussy Inst Gustave | Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines |
| CA2007083A1 (en) | 1989-01-09 | 1990-07-09 | Nobuhiko Katunuma | Pharmaceutical use of trypstatin |
| JP2813809B2 (ja) * | 1989-06-19 | 1998-10-22 | 武田薬品工業株式会社 | 有核顆粒製剤およびその製造法 |
| CS275231B2 (en) | 1989-09-29 | 1992-02-19 | Ustav Makormolekularni Chemie | Medicine bottle |
| FI920206A0 (fi) * | 1992-01-17 | 1992-01-17 | Pekka Untamo Heino | Medicinsk anvaendning, medicinskt foerfarande och preparat. |
| WO1996001623A1 (en) * | 1994-07-08 | 1996-01-25 | Astra Aktiebolag | Multiple unit tableted dosage form i |
| JPH08143476A (ja) * | 1994-11-18 | 1996-06-04 | Japan Tobacco Inc | 薬物放出制御膜及び固形製剤 |
| AU6353896A (en) | 1995-07-07 | 1997-02-10 | Novo Nordisk A/S | Production of proteins using bacillus incapable of sporulation |
| CN1195500C (zh) * | 1998-05-18 | 2005-04-06 | 武田药品工业株式会社 | 可口腔崩解的片剂 |
| CA2581111A1 (en) * | 1998-07-28 | 2000-02-10 | Takeda Pharmaceutical Company Limited | Rapidly disintegrable solid preparation |
| FI4533U1 (fi) * | 2000-03-14 | 2000-08-10 | Finnzymes Oy | Entsyymikoostumus maidon käsittelemiseksi |
| WO2002097064A1 (en) | 2001-05-29 | 2002-12-05 | Kao Corporation | Host microorganisms |
| FI112666B (fi) | 2001-11-06 | 2003-12-31 | Ipsat Therapies Oy | Itiöimätön Bacillus subtilis, sen valmistus ja käyttö |
| FR2843302B1 (fr) | 2002-08-09 | 2004-10-22 | Centre Nat Rech Scient | Forme galenique pour la delivrance colique de principes actifs |
| JP4749660B2 (ja) * | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
| EP1564286A1 (en) | 2004-02-11 | 2005-08-17 | Université de Liège | Hybrid proteins of beta-lactamase class A |
| AR051946A1 (es) * | 2004-11-05 | 2007-02-21 | Wyeth Corp | Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina |
| ES2429095T3 (es) | 2005-05-18 | 2013-11-13 | Da Volterra | Aporte colónico de adsorbentes |
| CN101410095B (zh) * | 2006-03-06 | 2015-07-01 | 波曾公司 | 施用组合药物的剂型 |
| FI119190B (fi) | 2006-06-21 | 2008-08-29 | Ipsat Therapies Oy | Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi |
| US8273376B2 (en) * | 2006-11-17 | 2012-09-25 | Da Volterra | Colonic delivery of metallo-dependent enzymes |
| FI119678B (fi) * | 2006-11-28 | 2009-02-13 | Ipsat Therapies Oy | Beta-laktamaasin käyttö |
| US9023352B2 (en) | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
| EP2566466A1 (en) * | 2010-05-03 | 2013-03-13 | Aptalis Pharma Limited | Micropellet compositions comprising pancreatin containing digestive enzyme mixtures |
| FI20105572A0 (fi) * | 2010-05-24 | 2010-05-24 | Prevab R Lcc | Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt |
| US9115079B2 (en) * | 2011-07-26 | 2015-08-25 | Meiji Seika Pharma Co., Ltd. | NDM inhibitor |
| CA2758556A1 (en) * | 2011-11-17 | 2013-05-17 | Pharmascience Inc. | Pharmaceutical composition of amphetamine mixed salts |
| US9433632B2 (en) * | 2011-11-30 | 2016-09-06 | Takeda Pharmaceutical Company Limited | Dry coated tablet |
| US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
| AU2015247382B2 (en) * | 2014-04-17 | 2020-04-23 | Theriva Biologics, Inc. | Beta-lactamases with improved properties for therapy |
| EP3236993B1 (en) * | 2014-12-23 | 2023-09-13 | Theriva Biologics, Inc. | Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics |
| EP3265119B1 (en) * | 2015-03-06 | 2023-10-11 | Theriva Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
-
2015
- 2015-10-08 ES ES15849110T patent/ES2806426T3/es active Active
- 2015-10-08 US US14/878,155 patent/US10105322B2/en active Active
- 2015-10-08 WO PCT/US2015/054606 patent/WO2016057744A1/en not_active Ceased
- 2015-10-08 CN CN201580059890.6A patent/CN107148473B/zh active Active
- 2015-10-08 MX MX2017004473A patent/MX2017004473A/es unknown
- 2015-10-08 JP JP2017516516A patent/JP6672277B2/ja active Active
- 2015-10-08 KR KR1020177012353A patent/KR102467968B1/ko active Active
- 2015-10-08 CA CA2962959A patent/CA2962959C/en active Active
- 2015-10-08 AU AU2015330937A patent/AU2015330937B2/en active Active
- 2015-10-08 EP EP15849110.0A patent/EP3204495B1/en active Active
-
2018
- 2018-08-24 US US16/111,477 patent/US10828260B2/en active Active
-
2020
- 2020-09-28 US US17/034,534 patent/US12178917B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015330937A1 (en) | 2017-05-25 |
| US20180360762A1 (en) | 2018-12-20 |
| WO2016057744A1 (en) | 2016-04-14 |
| JP6672277B2 (ja) | 2020-04-01 |
| KR102467968B1 (ko) | 2022-11-16 |
| CA2962959A1 (en) | 2016-04-14 |
| KR20170065649A (ko) | 2017-06-13 |
| CA2962959C (en) | 2023-04-04 |
| US10105322B2 (en) | 2018-10-23 |
| US20160101058A1 (en) | 2016-04-14 |
| US12178917B2 (en) | 2024-12-31 |
| AU2015330937B2 (en) | 2021-07-15 |
| EP3204495B1 (en) | 2020-04-22 |
| CN107148473A (zh) | 2017-09-08 |
| EP3204495A4 (en) | 2018-04-18 |
| US10828260B2 (en) | 2020-11-10 |
| EP3204495A1 (en) | 2017-08-16 |
| CN107148473B (zh) | 2021-08-06 |
| JP2017535521A (ja) | 2017-11-30 |
| US20210007994A1 (en) | 2021-01-14 |
| ES2806426T3 (es) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017004473A (es) | Formulaciones de betalactamasa y usos de las mismas. | |
| IL291922B1 (en) | FAP-activated medical materials and related uses | |
| PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
| MX2020004073A (es) | Procesos de siembra en serie y usos de los mismos. | |
| MX2021010886A (es) | Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
| EP3188721A4 (en) | Human therapeutic agents | |
| GB201603104D0 (en) | Therapeutic agents | |
| ZA201906271B (en) | Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament | |
| PH12017500602A1 (en) | Methods for treating ocular conditions | |
| GB201608797D0 (en) | Therapeutic use | |
| EP3302530A4 (en) | Cdh26 based therapeutic agents and their use | |
| PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| PL3129398T3 (pl) | Nowe środki medyczne i ich zastosowanie | |
| GB201700553D0 (en) | Therapeutic agents | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| EP3197470A4 (en) | Cis-gnetin h and trans-gnetin h as therapeutic agents | |
| PH12017500071A1 (en) | Therapeutic agent for keratoconjunctive disorder | |
| GB201600376D0 (en) | Novel therapeutic agents | |
| GB201620948D0 (en) | Therapeutic agents | |
| GB201616563D0 (en) | Therapeutic agents | |
| GB2558788B (en) | New therapeutic uses | |
| UA99992U (ru) | 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния | |
| GB201704107D0 (en) | New medical uses | |
| GB201702921D0 (en) | Therapeutic agent |